Prostate cancer is the third most common cancer in Malaysia with the lifetime risk of 1 in 117 men. Similar to many emerging economies, there is a growing number of cases in Malaysia, and it seems that there is a connection between the occurrence of cancer and the level of prosperity. The excessive intake of red meat is believed to play a role in the development of cancer, and there is also a relationship between obesity and diabetes, both of which are common conditions in Malaysia. With men experiencing longer lifespans, there is a noticeable rise in the incidence of prostate cancer.
Cancer management has long been a subject of debate, with various treatment options available for patients depending on the severity and aggressiveness of the disease. However, a recent study in the US has shed light on an alternative approach known as active surveillance, which is gaining recognition for its effectiveness in managing low-risk prostate cancer cases.
The Canary PASS study, conducted by researchers from the Fred Hutch Cancer Center, has shown promising results in the use of active surveillance as a disease management protocol for prostate cancer. This approach involves regular monitoring through biopsies, prostate-specific antigen (PSA) testing, and other screening methods to track the growth of cancer cells while avoiding unnecessary treatment and associated medical costs.
Over a period of nearly 10 years, the study followed more than 2,300 patients across 10 treatment centres in North America. The results revealed that active surveillance was a safe and effective strategy for managing favourable risk prostate cancer. The protocol not only effectively managed the disease but also significantly reduced overtreatment among patients.
One of the key findings of the study was that almost half of the participants did not experience any cancer progression or require treatment ten years after their initial diagnosis. Additionally, the incidence of metastatic cancer was found to be less than 2% within the entire cohort, with less than 1% of patients succumbing to the disease. These results highlight the potential benefits of active surveillance in preventing unnecessary interventions for slow-growing prostate cancer cases.
Experts in the field have expressed optimism about the implications of these findings. The long-term follow-up provided by the study reinforces the importance of avoiding immediate treatment for low-grade prostate cancer. The insights gained from the Canary PASS study are expected to have a significant impact on clinical decision-making for both patients and healthcare providers.
Active surveillance involves a comprehensive monitoring process that includes PSA testing, prostate biopsies, and optional diagnostic tests such as MRI and biomarker assessments. The Canary PASS protocol establishes a structured testing schedule, ensuring that patients receive timely and appropriate monitoring to assess the progression of their cancer.
PSA testing is initially conducted every three months, with biopsies performed at six months and one year after diagnosis. Subsequently, the frequency of biopsies is reduced to once every two years after the initial two-year period. Optional tests such as MRI and biomarker assessments can be carried out at the discretion of the healthcare provider, offering additional insights into the progression of the disease.
The implementation of a clear and structured protocol for active surveillance is seen as a significant advancement in prostate cancer management. By providing guidelines on when and how testing should be conducted, the Canary PASS protocol ensures high adherence among patients and clinical teams across different healthcare settings.
The significance of a confirmatory biopsy within a year after diagnosis is underscored as a crucial step in the active surveillance process. This biopsy serves to validate the need for ongoing monitoring and helps healthcare providers determine the appropriate course of action for each patient. Despite its importance, studies have shown that a substantial number of individuals diagnosed with low-risk prostate cancer do not undergo a confirmatory biopsy, highlighting the need for greater awareness and adherence to established protocols.
The success of active surveillance in managing low-grade prostate cancer lies in its ability to tailor treatment decisions based on individual patient needs. By closely monitoring disease progression and utilising a range of diagnostic tools, healthcare providers can make informed decisions about when intervention is necessary to prevent disease advancement while avoiding unnecessary treatments and their associated risks.
The implications of the Canary PASS study extend beyond clinical outcomes to impact decision-making processes for patients and clinicians alike. The availability of a structured protocol for active surveillance offers reassurance to individuals with low-risk prostate cancer, indicating that a watchful waiting approach can yield positive health outcomes without compromising long-term prognosis.
The findings from the Canary PASS study highlight the effectiveness of active surveillance as a management strategy for low-risk prostate cancer. By providing a structured approach to monitoring disease progression and guiding treatment decisions, this protocol offers a valuable alternative to immediate intervention for patients with slow-growing prostate cancer. As research in this field continues to evolve, active surveillance is poised to play an increasingly prominent role in optimising outcomes for individuals with favourable risk prostate cancer.
